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ABSTRACT
Importance: Coronavirus 2019 pandemic (COVID 19) is caused by the Severe acute respiratory syndrome coronavirus 2 (SARS CoV-2)
virus. The pandemic is affecting the livelihood of millions of people all over the world. At the time of preparing this report, the pandemic has
affected 1 827 284 patients, with 113 031 deaths in 185 countries as per Johns Hopkins University. With no proven treatment for the disease,
prevention of the disease in the community and healthcare setting is need of the hour.
Objective: To perform a comprehensive literature search for preventive measures and experimental treatment options. In this review, we
have focused our discussion on the risk of disease transmission, supportive treatment, and possible treatment options based on available
evidence.
Evidence Review: We performed a literature search on google scholar, PubMed, and society guidelines for literature related to COVID
19 and previous coronavirus pandemics. We included data review articles, observational studies, and controlled trials to synthesize the treatment options for COVID 19.
Findings: In this article, we have extensively reviewed and discussed recommendations from various world organizations for the public
and healthcare workers. We have also discussed currently available experimental treatments since there is no proven treatment for COVID
19. The best method of dealing with the current outbreak is to reduce the community spread and thus “flatten the curve.” Although Hydroxychloroquine, Remdesivir, Lopinavir/Ritonavir, and Azithromycin have been tried, passive immunity through convalescent serum and vaccine
is still at an experimental stage. Patients with severe COVID 19 infections could be considered for this experimental treatment through various national randomized control trials, which may eventually lead to an evidence-based treatment strategy.
Conclusions and Relevance: Awareness of currently available experimental treatment among healthcare providers and exploration
of possible treatment options through evidence is need of the hour. We have discussed the most recently available literature and evidence
behind experimental treatment in this article.
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Background

1 827 284 patients have been diagnosed with a confirmed infection in 185 countries, with 113 031 deaths as per Johns Hopkins
University.
The virus causes animal and human diseases affecting respiratory and gastrointestinal systems. The disease can be transmitted to when humans come in contact with secretions and
body fluids of infected animals either through droplets or consumption of infected meat. Once the virus comes in contact
with human respiratory and gastrointestinal mucosa, it uses
entry receptors angiotensin-converting enzyme 2 (ACE2) to
enter the human cells3,4. Transmission of disease between
humans happens through secretions, droplets, and fecal-oral

The current coronavirus pandemic (COVID 19) is caused by
Severe acute respiratory syndrome coronavirus 2 (SARS CoV
2), a positive-sense single-stranded RNA virus. The initial disease outbreak started in China as a cluster of pneumonia due to
unclear etiology. The disease was linked to contact with the
seafood and wet animal market in Wuhan city of Hubei province of China.1 Eventually, the virus was identified as a novel
coronavirus and named as SARS-CoV-2 by the World Health
Organization (WHO).2 The virus spread exponentially over
the next few weeks to several countries, and WHO declared it
as a pandemic on 11 March 2020. Since then, more than
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contamination. The virus has been detected in sputum, nasopharyngeal secretions, respiratory droplets, blood, stool, and
urine samples5. At this time, there is no evidence to suggest
vertical transmission to the fetus during pregnancy. Experience
in treating pregnant women with COVID 19 lacks to make a
clear determination at this time6. The estimated incubation
period for the SARS-CoV-2 virus is around 14 days, with a
median of 4-5 days7. Common symptoms of COVID-19
include fever, cough, shortness of breath reported in more than
70% of patients. Other symptoms include headache, and myalgia. Gastrointestinal symptoms such as nausea, vomiting,
abdominal pain, diarrhea, dysgeusia, anosmia, and liver involvement have also been observed7,8,9.

Preventive measures

Precautions for prevention of SARS-CoV-2 transmission is
the avoidance of contact with infected patients. The Center for
Disease Control (CDC) has made several recommendations to
the general population, including; hand hygiene, avoiding contact, and clean and disinfect.
Hand hygiene: Washing hands with soap and water for at
least 20 seconds or using alcohol-based hand sanitizers with at
least 60% alcohol content covering all the areas can kill the virus.
Avoiding close contact: The most common mode of transmission between humans is through respiratory droplets.
Maintaining at least 6 feet distance from anybody suspected of
infection reduces the chance of droplet infection. However,
there have been documented cases of COVID transmission
from asymptomatic carriers without any disease manifestations. Those who are sick should stay home and seek medical
help if symptoms are worsening or deteriorating. If someone is
sick, they should wear a mask to reduce the risk of transmission
to others.10 The most important and widespread intervention
to prevent the rapid increase in cases is through social distancing. Center for disease control recommends at least 6 feet distance between individuals to prevent community spread of
COVID 19. Various state governments, including New York
and California, have implemented statewide stay home, and
more states are following similar social distancing.11 The main
aim of the goals is to flatten the epidemiological curve and
reduce the total number of sick patients at a given time. This
strategy will help hospitals to use their resources in a manner
without compromising care for anybody. However, with the
rising death toll in Italy and elsewhere in the world, the rise in
the number of sicker patients requiring inpatient hospital care
is expected.

Clean and disinfect
It is already established that the COVID virus can survive on a
variety of objects, fomites, and surfaces, including plastic, steel,
and medical instruments, for up to 72 hours at infectious titers.12
Although there is no documented case of COVID 19 transmission from the surface to humans, the possibility is real. CDC

recommends using bleach 5 tablespoon bleach in 1 gallon of
water or alcohol-based disinfectant with at least 70% alcohol.

Prevention of COVID 19 transmission in
healthcare institutions
The transmission of COVID 19 in the health care setting
can prove deadly. Since health care workers starting from
receptionists, nurses, phlebotomists, and treating physicians
all are at risk of contracting COVID 19 through various
body fluids and respiratory droplets, it is paramount to practice all safety precautions. All patients with suspected or confirmed COVID 19 infection should be isolated with contact,
airborne, and droplet precautions with negative pressure ventilation rooms. Whenever the patient needs to be transferred
to the procedure room or operative theaters, patients should
wear a surgical mask.
The most important rule in caring for COVID 19 patients
is to minimize the number of healthcare workers exposed. Any
non-essential members such as residents, fellows who are not
making critical decisions should be assigned for other tasks
such as answering COVID 19 helplines and telemedicine virtual visits.
Any healthcare workers who come in contact with suspected
on confirmed COVID 19 patients should follow the following
basic personal protection measures before entering the room:
a.
b.
c.
d.
e.

Gloves
Disposable waterproof gown
Face shield or Eyeshields/goggles
N95 or other high filters respirators (FFP2 and FFP3)
Hand wash with soap and water or disinfectant hands
with alcohol-based sanitizers that have at least 60%
alcohol before and after entering the room

Cleaners who clean the rooms that are occupied by the COVID
19 patients should also follow the above precautionary measures. They should remove the glove, and dispose of them
according to biohazards management per institutional policy
after cleaning.13,14

Supportive treatment

Most patients with COVID 19 (80%) will recover from
infection with minor symptoms of upper respiratory tract
infection such as fever, cough, sputum production, and myalgia.15 However, it is not clear what percentage of the infected
patients will require hospitalization and what percentage of
hospitalized patients would end up requiring intensive care
unit stay.
In 1 study involving 204 confirmed COVID patients, 7.8%
of the patients required intensive care unit stay, and 17.6% of
the patients died despite treatment.16 As per available evidence,
an overall case fatality rate of 2.3% to 3.6% has been observed.5,17
However, the case fatality rate (CFR) is significantly higher for
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critical care trained nurses. This can increase the mortality
during COVID 19 outbreak. One of the most important
aspects of caring for ARDS is low pressure and low volume
lung-protective strategy. Guidelines suggest low tidal volume
(<6 ml/kg), plateau pressure (<30 m Hg), arterial pH <7.30,
Oxygenation (PaO2 > 55, SpO2 between 88% and 95%.
And weaning off of the ventilator should be attempted when
Fio2/PEEP < 0.40/8.20
With a possibility of ventilator shortage during the COVID
19 pandemic, it is important to utilize personnel and equipment such as ventilators efficiently. In an experimental pilot
study, a single ventilator was connected to 4 lung simulator
bags representing 4 different patients. Although the study
found that it was theoretically possible to manage 4 patients on
a single ventilator, there were several limitations.21

Figure 1. Treatment algorithm for COVID 19 treatment.

elderly patients and those with comorbidities and immunosuppression as high as 14.8%. In the same study, the CFR for
patients that were diagnosed as critical had mortality of 49%.18
Figure 1 shows an algorithm for the treatment of COVID 19
during inpatient care.
While symptomatic treatment with NSAIDs, treatment
of secondary bacterial infections with antibiotics is the
mainstay of treatment for COVID 19 patients, sicker
patients may need respiratory support ranging from nasal
cannula oxygen to ventilator support. Hospitals, medical,
and surgical societies are recommending to reschedule any
non-urgent procedures to mobilize resources for critically ill
patients.14
Severe COVID 19 is defined as those who have at least 1 of
the following symptoms including shortness of breath, respiratory frequency ⩾ 30/minutes, oxygen saturation in the blood
⩽ 93%, the partial pressure of arterial oxygen to fraction of
inspired oxygen ratio < 300, or lung infiltrates > 50% within
24 to 48 hours. The life-threatening disease is defined as 1 or
more of these symptoms: respiratory failure, or septic shock, or
multiple organ dysfunction or failure.19

Respiratory support
Patients with severe disease usually develop pulmonary
symptoms due to acute respiratory distress syndrome, and
the most common cause of death is hypoxemia. Therefore,
respiratory support with a ventilator can reduce mortality
drastically. However, if there is a massive rise in the number
of cases and the need for ventilatory support is going to be
significantly high. Hospitals do not have the capacity to
manage such a high number of patients with critical care
needs. There are not enough critical care providers or other
resources such as ventilators, respiratory therapists, and

Anti-hypertensive medications and antiinflammatory medications
Non-steroidal anti-inflammatory drugs (NSAIDs) are commonly used in the symptomatic treatment for the treatment of
most viral illnesses. A recent correspondence letter published in
a major medical journal suggested that the use of Angiotensinconverting enzyme inhibitors and angiotensin receptor blockers (ARBs) among patients with hypertension and diabetes
may have upregulated ACE2 receptors. Similarly, ibuprofen
and thiazolidinediones also cause the upregulation of ACE2
receptors. Since SARS-CoV-2 uses ACE2 receptors to enter
the host cell, it was hypothesized that these patients might
develop severe and COVID 19.22 However, there is no proven
benefit or adverse effect of NSAIDs or ARBs observed in the
treatment of COVID 19. Future research on the topic may be
necessary before we can make any further determinations.
Corticosteroids are the other potent anti-inflammatory
medication that has been used in the treatment of COVID.
However, there is no clinically proven benefit or harm in
using corticosteroids in the treatment, and therefore, further
studies are needed to evaluate corticosteroids for the treatment of COVID.

Review of experimental treatments

Currently, there is no clinically proven medication available for
the treatment of COVID 19 patients. Various agents such as
Hydroxychloroquine, Lopinavir/Ritonavir, Remdesivir, and
Azithromycin are being evaluated. Other experimental medications include interleukin 6 antibodies (tocilizumab).23 Table 1
lists the medications, dosage, administration, and monitoring
required while treating COIVD 19 patients.

Antimalarial drugs: Chloroquine and
hydroxychloroquine
Antimalarial drug chloroquine has shown in vitro activity
against multiple viruses, including Enterovirus EVA71, zika
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Table 1. Medications available and important information.
Drugs

Dosage

Mechanism

Administration

Drug monitoring

Hydroxychloroquine
(Plaquenil ®). NOT
FOR USE AS
PROPHYLAXIS

400 mg
(2 × 200 mg
tablets) PO
q12h × 2 doses
on day 1, then
200 mg PO q12h
on days 2-5

Alter pH at the
surface of the cell
membrane and
inhibit nucleic acid
amplification

Administer tablets
with a meal. If
needed, crush and
allow at least 5 min to
disperse the tablet in
water.

Adverse events: retinal pathology, cardiac
effects including cardiomyopathy and QTc
prolongation, worsening of psoriasis/
porphyria, myopathy, neuropathy,
neuropsychiatric events, hypoglycemia
Contraindications: QTc > 500 msec drug
interaction; Myasthenia gravis Porphyria
Retinal pathology Epilepsy

Azithromycin

500 mg day 1,
then 250 mg day
2-5

Synergy with
hydroxychloroquine

Can be administered
IV or PO given in
combination with
Hydroxychloroquine

*MONITOR CLOSELY FOR QTC
PROLONGATION AS BOTH
AZITHROMYCIN AND
HYDROXYCHLOROQUINE MA

Lopinavir/ritonavir
(Kaletra®)

400/100 mg
(2 × 200/50 mg
tablets) PO BID
for up to 14 d

Inhibition of viral
protease

Administer tablets
with or without meals.
Not crushable

Adverse events: GI intolerance, pancreatitis,
asthenia, hyperlipidemia, transaminase
elevation, hyperglycemia, insulin resistance/
diabetes mellitus, fat maldistribution, possible
increase in the frequency of bleeding
episodes in patients with hemophilia, EKG
changes. Please obtain an HIV test prior to
initiation and check for drug-drug interactions

Darunavir/ritonavir
(Prezista®/Norvir ®)

800/100 mg PO
daily (ordered
as 1 tablet of
each agent
daily)

Inhibition of viral
protease

THE TWO TABLETS
MUST BE GIVEN AT
THE SAME TIME.
Administer tablets
with a meal. Not
crushable

Adverse events: skin rash, hepatotoxicity, GI
intolerance, headache, hyperlipidemia, serum
transaminase elevation, hyperglycemia, fat
maldistribution, possible nephrotoxicity with
cobicistat Please obtain an HIV test prior to
initiation and check for drug-drug interactions

virus, influenza A H5N1, and human coronaviruses.24-27
Currently, efforts are being made to evaluate hydroxychloroquine in the treatment of SARS-CoV-2 infection. However, a
similar hypothesis tested in a randomized double-blinded
placebo-controlled trial for the treatment of H5N1 influenza
during the outbreak in 2011 did not prevent infection.28
Similarly, the treatment of Ebola infection with chloroquine
also failed to show benefits.29
Chloroquine and hydroxychloroquine can prevent the cellular entry of the SARS-CoV-2 virus and thus preventing viral
replication and, thus, the disease. SARS-CoV-2 utilizes spike
(S) protein to bind to ACE2 receptors for cell entry.
Chloroquine and hydroxychloroquine reduce the endosomal
pH, prevent virus-cell fusion, and interfere with glycosylation
of ACE2 receptors. This prevents spike protein from binding
to entry (ACE2) receptors and thus preventing the viral
replication.30-32
Initial experience to treat COVID 19 with chloroquine from
Chinese hospitals has shown to reduce the severity of pneumonia, viral clearance, duration of symptoms with minimal side
effects.33 In another nonrandomized control study combination
of hydroxychloroquine and azithromycin led to virologic cure at
day 6 in 100% of the patients, whereas only 70% of the patients
with hydroxychloroquine as monotherapy and 12.5% in the
controlled group.34 Larger randomized control trials are needed
to establish the benefit of chloroquine and hydroxychloroquine
in the treatment of COVID 19. In a recent update, the United
States Food and Drug Administration has cautioned about the

use of either Chloroquine or hydroxychloroquine since they
have not shown to be safe and beneficial based on preliminary
results, as well as concern regarding cardiotoxicity.35 Therefore,
their use has been restricted to clinical trials only.

Antiviral agents
Normal interferon response is a critical defense against viral
infection and replication in the host cells. Beta coronaviruses
such as Severe acute respiratory syndrome (SARS) virus,
Middle Eastern Respiratory Syndrome (MERS), and SARSCoV-2 (COVID19) viruses induce downregulation of interferon response which is critical to their pathogenicity.36
Several antiviral agents have been proposed for the treatment
of COVID.
1) Remdesivir: Remdesivir is a broad-spectrum antiviral
agent with activity against several viruses, including paramyxoviruses, filoviruses, and human coronaviruses such as
MERS and SARS. Remdesivir is an adenosine nucleotide
analog shown to prevent MERS infection when given prophylactically and reduce the viral load, pulmonary symptoms when given in early disease in animal studies.37,38
In an in vitro study effect of medications targeting RNA
dependent RNA polymerase (RdRp) of SARS CoV-2
was tested. And among them, Remdesivir, Galidesivir,
Ribavirin, Sofosbuvir, ant Tenofovir were able to bind to
the RdRp with sufficient binding energy, and this can
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interfere in the replication of SARS CoV-2. Other
agents with anti-RdRp agents under consideration are
Setrobuvir, IDX-184 (a guanosine derivative), and
YAK.39 Lopinavir was also able to inhibit viral replication in another in vitro study; however, Ribavarin failed
to inhibit virus replication in this study.40
In a recent cohort prospective study involving 53 patients
with confirmed COVID 19 requiring supplemental O2, a
ten-day course of Remdesivir was administered. At the
end of 18 days follow up, and improved oxygen support
class was observed. Among patients requiring mechanical
ventilation, 57% (17 of 30) were extubated, and 47% (25
of 52) patients were discharged home. Mortality of 13%
(7/52) was noted, of which mortality was 18% among
those requiring invasive ventilation (mechanical ventilation or extracorporeal membrane oxygenation).41 Further
larger randomized, double-blinded, placebo-controlled
trials are underway and would provide further information necessary to evaluate its efficiency in the near future.
2) Lopinavir/Ritonavir: Lopinavir is a protease inhibitor
against HIV 1 when combined with ritonavir has shown
activity against the SARS virus both in vitro and humans.
Ritonavir is given in this combination to improve the
plasma concentration of lopinavir. In a randomized control trial, a triple-drug regimen with Lopinavir/ritonavir
and interferon-beta is being studied for MERS.42 In
another human transgenic mouse study, prophylactic and
therapeutic properties of Remdesivir are being compared
to Lopinavir/ritonavir and interferon-beta combination
for the treatment of MERS.43
In a randomized control trial conducted in Wuhan province of China, Lopinavir/ritonavir was compared to standard treatment. The study showed no significant
improvement in clinical improvement with lopinavir/ritonavir (Hazard ratio 1.24, 95% confidence interval [CI],
0.90 to 1.72). Also, there was no significant difference in
mortality between the treatment group and the control
group (12% vs 17%, 95% CI −17.3 to 5.7). Since this study
was open-labeled, there is a high risk of bias.44 Therefore,
true double-blinded randomized control trials are needed
to understand their benefit in the treatment of COVID 19.

Immunomodulators
Patients with acute respiratory distress syndrome (ARDS) in
COVID 19 were noted to have cytokine storm of interleukin 6
(IL 6), interleukin 2, interleukin 7, interleukin 10, tumor necrosis factor α (TNF α), granulocyte-colony stimulating factor
(G-CSF), interferon-γ-inducible protein (IP10) and many
other cytokines.45,46 Among these cytokines, IL 6 and G-CSF
are the most important that lead to inflammation causing disruption of alveolar blood gas exchange, impaired oxygenation,
and organ failure.

5

1) Corticosteroids. During the initial phase of the COVID-19
pandemic, the use of corticosteroids was in the treatment of
severe COVID-19 was controversial. Immunosuppression due
to corticosteroids could lead to increased susceptibility for secondary infection and worsen the outcome. However, the latest
results show that corticosteroids may be beneficial. In a randomized control trial involving 6,425 patients, dexamethasone
was administered to 2,104 patients, and 4,321 patients received
usual care. The study showed that the 28-day mortality was
significantly lower in the dexamethasone group (0.83; 95%
Confidence Interval (CI) 0.75-0.93; p<001) when compared to
usual care. The beneficial effects were mostly seen in those who
had severe COVID-19 and not among those who were not
receiving respiratory support.47 Similarly, a meta-analysis of
preliminary results from seven randomized control trials, corticosteroids significantly reduced the all-cause mortality (Pooled
odds ratio 0.64 (95% CI, 0.50-0.82; P < .001).48
Current recommendations from the National Institute of
Health suggests the use of dexamethasone 6mg per day for up
to 10 days. If dexamethasone is not available, alternative corticosteroids such as prednisone, methylprednisolone, and hydrocortisone can be considered. However, the guidelines suggest
against the use of corticosteroids for those who do not require
supplemental oxygen.49
2) Tocilizumab: Interleukin 6 receptor monoclonal antibody. Tocilizumab is an interleukin 6 receptor monoclonal
antibody used in the treatment of rheumatoid arthritis.50
Tocilizumab binds to the IL 6 receptors and blocks the transmembrane signal transduction pathway that is responsible for
the pro-inflammatory role of IL 6.
In a retrospective study, 21 patients with severe COVID 19
were treated with tocilizumab. Eighteen patients received just
1 dose, and 3 patients received a second dose. The study
observed significant improvement in symptoms, improved oxygenation and reduced O2 demand (75%), a significant improvement in lymphocyte count (89.5%), improved lung infiltrates
in 90% of the patients and 19 patients were discharged with no
mortality at the time when the mean duration of hospitalization 13.5 ± 3.1 days.51 It is a retrospective observational cohort
study involving a small number of patients, and its results may
not be generalizable. However, COVID 19 has no proven
treatment, and a larger randomized, double-blinded controlled
study is needed to further evaluate its efficacy. A recent metaanalysis has shown that the addition of Tocilizumab to the
standard of care may reduce mortality.52 However, the results
were limited by the inclusion of observational studies only.
3) TNF α inhibitors. As previously described, ACE2 receptors
play an important role in viral entry into the human cells and
are responsible for lung injury.3 It is observed that spike protein
from the SARS CoV-2 virus causes TNF α converting enzymedependent shedding of ACE2 ectodomain.53 This is critical in
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viral entry into the cell for replication. Therefore, it is postulated that TNF α receptor blockers can reduce viral entry into
human cells and can reduce organ damage. A clinical trial in
China is evaluating the efficacy of adalimumab in COVID 19
patients (ChiCTR2000030089).

infection through the amplification of RNA sensing and Type
1 interferon response.60,61 Currently, there are no clinical trials
using emetine or nitazoxanide at this time. However, in search
of an effective treatment for SARS CoV-2, these antiprotozoal medications should be explored.

Passive immunity with convalescent serum

2) Homorringtonine. Homorringtonine is a plant alkaloid
with antitumor activity by binding to the ribosomal A site and
inhibits protein synthesis. Omacetaxine is a semi-synthetic
form of homorringtonine approved for the treatment of chronic
myeloid leukemia. Homorringtonine is also a broad antiviral
agent with activity against Herpes viruses, coronaviruses, hepatitis B, and echoviruses.62,63 In an in-vitro study, homorringtonine was able to inhibit SARS-CoV-2. This indicates
Omacetaxine could be a potential anti-COVID 19 medication
that needs further reconsideration.

Convalescent serum with polyclonal antibody products has
been used in the treatment of acute infections with cytomegalovirus, hepatitis B, and varicella-zoster. Similar strategies can
be considered in the treatment of COVID 19. However, determination of effectiveness and dose in the treatment of COVID
19 are not known at this time and need to be studied extensively before being available for treatment.
In a small observational study of 5 patients requiring
mechanical ventilation and getting antiviral medications,
administration of convalescent serum led to resolution of fever
in 3-4 days, oxygenation improved, and ARDS resolved in 4
patients, 3 patients were weaned off of mechanical ventilation
at the end of 12 days. Three patients were discharged, and no
mortality observed. The remaining 2 patients remained stable
at 37 days.54 However, this is a small study, and the results may
not be generalizable.
Recently, the United States Food and drug administration
approved the use of convalescent serum for confirmed COVID
19 patients with a severe or life-threatening disease. The convalescent serum donors should have a laboratory-confirmed
COVID 19 or have SARS-CoV-2 antibodies, and they should
have complete resolution of symptoms at least 28 days before
donating or should have at least 14 after the resolution of
symptoms and should test negative for SARS CoV-2. Currently,
the convalescent serum can only be used with FDA approval
either through a clinical trial or for single patient use in emergent cases.19

Development of vaccine
The SARS-CoV-2 virus gains access into the host cells using
spike protein. This is essential for pathogenicity, and a vaccine
targeting the spike protein is being evaluated.30 National
Institute of health is carrying out animal studies, and a phase 1
human trial has begun in Seattle, WA.55

Prognosis. As previously discussed, nearly 80% of the patients
are improving without any significant medical help. Most
patients who develop severe diseases likely have a severe respiratory illness, and it is more common among the elderly with
poor prognosis. Further, approximately 14% percent of patients
will need inpatient hospital admission and intensive care may
be required in 2% of the patients with up to 5% mortality.7
Corticosteroids are the only medications that have shown mortality benefit in the treatment of severe COVID-19. Results
from larger randomized control trials may provide us better
insights into effective treatment.
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